Applied Therapeutics(APLT) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Applied Therapeutics Reports Second Quarter 2024 Financial Results - NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in early Q1 2025 - FDA Genetic Metabolic Diseases Advisory Committee (GeMDAC) Meeting to discuss NDA for govorestat for the treatment of Classic Galactosemia tentatively scheduled for October 9, 2024 - Company aligned with the Neurology I Division on ...